玛雅吧

中

中文 English

About Us
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
- Company News
- Media Focus
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
Products
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
R&D
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Contact Us
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.



Shengfuda (Sunitinib Malate Capsules)

Sunitinib Malate Capsules

English Name: Sunitinib Malate Capsules

Chinese Pinyin: Pingguosuan Shunitini Jiaonang

The main ingredient of this product is sunitinib malate.

Chemical Name: (Z)-N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-3-carbamoyl-1H-pyrrole malate

/en/upload/images/2021/06/17/424132d60e56456e93855ccbb7efa2d0.png

【Name】	Common Name: Sunitinib Malate Capsules English Name: Sunitinib Malate Capsules Chinese Pinyin: Pingguosuan Shunitini Jiaonang
【Ingredients】	Main Ingredient: sunitinib malate Chemical Name: (Z)-N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-3-carbamoyl-1H-pyrrole malate Structural Formula: Molecular Formula: C₂₂H₂₇FN₄O₂·C₄H₆O₅ Molecular Weight: 532.56 Excipients: mannitol, polyvinylpyrrolidone, crosslinked sodium carboxymethyl cellulose, and magnesium stearate
【Description】	This product is a capsule with the content of yellow to orange granules.
【Indication】	1) Inoperable advanced renal cell carcinoma (RCC) 2) Imatinib mesylate failed or intolerable gastrointestinal stromal tumor (GIST) 3) Unresectable, metastatic well-differentiated advanced pancreatic neuroendocrine tumor (PNET) in adult patients.
【Strength】	12.5mg (as sunitinib)
【Dosage and Administration】	The recommended dose of sunitinib in the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma is 50mg orally once daily for 4 weeks with a 2-week discontinuation period (4/2 dosing regimen). For pancreatic neuroendocrine tumor, the recommended dose of sunitinib is 37.5mg orally once daily with no discontinuation period. It can be taken with or without food. Note: Please refer to the Product Manual for details.